• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B

    2010-06-29 10:13:48LuWenWangHuiChenandZuoJiongGong

    Lu-Wen Wang, Hui Chen and Zuo-Jiong Gong

    Wuhan, China

    High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B

    Lu-Wen Wang, Hui Chen and Zuo-Jiong Gong

    Wuhan, China

    BACKGROUND:Liver failure in chronic hepatitis B (CHB) patients is a severe, life-threatening condition. Intestinal endotoxemia plays a significant role in the progress to liver failure. High mobility group box-1 (HMGB1) protein is involved in the process of endotoxemia. Regulatory T (Treg) cells maintain immune tolerance and contribute to the immunological hyporesponsiveness against HBV infection. However, the roles of HMGB1 and Treg cells in the pathogenesis of liver failure in CHB patients, and whether HMGB1 affects the immune activity of Treg cells are poorly known at present, and so were explored in this study.

    METHODS:The levels of HMGB1 expression were detected by ELISA, real-time RT-PCR, and Western blotting, and the percentage of CD4+CD25+CD127lowTreg cells among CD4+cells was detected by flow cytometry in liver failure patients with chronic HBV infection, CHB patients, and healthy controls. Then, CD4+CD25+CD127lowTreg cells isolated from the peripheral blood mononuclear cells from CHB patients were stimulated with HMGB1 at different concentrations or at various intervals. The effect of HMGB1 on the immune activity of Treg cells was assessed by a suppression assay of the allogeneic mixed lymphocyte response. The levels of forkhead box P3 (Foxp3) expression in Treg cells treated with HMGB1 were detected by RT-PCR and Western blotting.

    RESULTS:A higher level of HMGB1 expression and a lower percentage of Treg cells within the population of CD4+cells were found in liver failure patients than in CHB patients (82.6±20.1 μg/L vs. 34.2±13.7 μg/L; 4.55±1.34% vs. 9.52± 3.89%, respectively). The immune activity of Treg cells was significantly weakened and the levels of Foxp3 expression were reduced in a dose- or time-dependent manner when Treg cells were stimulated with HMGB1in vitro.CONCLUSIONS:The high level of HMGB1 and the low percentage of Treg cells play an important role in the pathogenesis of liver failure in patients with chronic HBV infection. Moreover, HMGB1 can weaken the immune activity of Treg cells. It is suggested that effectively inhibiting HMGB1 expression could be a feasible way to treat liver failure by suppressing endotoxemia and enhancing Treg cell activity.

    (Hepatobiliary Pancreat Dis Int 2010; 9: 499-507)

    high mobility group box-1 protein; regulatory T cells; chronic hepatitis B; liver failure

    Introduction

    HBV infection is a major public health problem worldwide, especially in China.[1-3]Some patients with chronic hepatitis B (CHB) progress towards acute or subacute-on-chronic liver failure, which is a severe life-threatening condition with a high fatality, and effective treatment is lacking.[4]A lot of evidences indicate that intestinal endotoxemia plays a significant role in the occurrence and progression of liver failure in CHB patients.[5-8]The gut is a vast pool of bacteria and endotoxin (lipopolysaccharide, LPS). When large quantities of endotoxin are produced by overgrowth of Gram-negative bacteria in the gut, and/or bacteria are translocated into the peritoneal cavity due to the high permeability of the intestinal wall, endotoxemia is generated because the levels of endotoxin in the portal vein surpass the hepatic capacity for endotoxin scavenging. Then, endotoxin spills over into the systemic circulation, which aggravates liver injury and induces liver failure.[5-7]

    Previous studies have shown that high mobility group box-1 (HMGB1) protein, a late inflammatory mediator, is involved in the progression of endotoxemia.[9-12]HMGB1 was originally identified as a DNA-binding protein that functions as a structural co-factor criticalfor proper transcriptional regulation and nucleosome stabilization.[13-15]In addition, HMGB1 is released into the extracellular milieu from activated macrophages, immuno-stimulated gut epithelial cells, and necrotic or damaged cells in a delayed manner relative to the secretion of other proinflammatory mediators, such as TNF-α and IL-1, and contributes to the pathogenesis of diverse inflammatory and infectious disorders.[16-18]A growing number of studies indicate that HMGB1 is a successful therapeutic target in experimental models of ischemia-reperfusion injury, acute respiratory distress syndrome, rheumatoid arthritis, sepsis, and cancer.[19-23]Since intestinal endotoxemia is closely related to the progression of liver failure in CHB patients, it is hypothesized that HMGB1 as an important inflammatory mediator of endotoxemia likely plays a significant role in the pathogenesis of liver failure in CHB patients.

    Regulatory T (Treg) cells are a specialized subpopulation of CD4+T cells that are responsible for the balance of immune responses, maintaining peripheral tolerance, preventing autoimmune diseases, and limiting chronic inflammatory diseases.[24-26]Several studies have shown that Treg cells play an important role in maintaining immune tolerance and contributing to immunological hyporesponsiveness against HBV infection.[27-30]Therefore, Treg cells may limit liver injury by controlling inflammation and reducing the incidence of liver failure in CHB patients. However, the roles of Treg cells in the pathogenesis of liver failure in CHB patients are poorly known at present.

    In the present study, the levels of HMGB1 expression and the percentage of CD4+CD25+CD127lowTreg cells within the CD4+cell fraction were assessed in liver failure patients with chronic HBV infection to investigate the roles of HMGB1 and Treg cells in the pathogenesis of liver failure. In addition, by suppression assay of CD4+CD25+CD127lowTreg cells isolated from the peripheral blood mononuclear cells (PBMCs) of CHB patients after treatment with HMGB1 at various concentrations and times, the effects of HMGB1 on immune activity of Treg cells were also studied.

    Methods

    Isolation of PBMCs

    Patients were diagnosed with CHB and liver failure according to the criteria from the program of prevention and cure for viral hepatitis amended at the Xi'an meeting held in September 2000 by the Chinese Society of Infectious Disease and Parasitology and the Chinese Society of Hepatology of the Chinese Medical Association.[31]The major diagnostic criteria included basic conditions, and serum bilirubin in the liver failure index ten times higher than normal (17.1 μmol/L), i.e. above 171.1 μmol/L. Two additional conditions were at least one liver failure index or more than one of the following indices: 1) prothrombin activity <40% or international normalized ratio ≥1.5; 2) hepatic encephalopathy; 3) ascites; 4) progressive reduction of liver size; and 5) hepatorenal syndrome. Patients coinfected with HIV, HAV, HCV, HDV, or HEV were excluded from this study. Patients and controls who were immunocompromised or pregnant and patients who had received antiviral or immunomodulatory treatment against HBV during the last 6 months before blood sampling were also excluded. Patients with autoimmune hepatitis, alcohol abuse (≥80 g ethanol/day), and HCC diagnosed within 3 months were not enrolled. Informed consent was obtained from the all participants before blood donation. The study protocol was approved by the local ethics committee.

    Heparinized peripheral blood samples were obtained from 15 liver failure patients with chronic HBV infection, 20 CHB patients, and 10 healthy controls. PBMCs from all participants were obtained by density gradient centrifugation using Lydroxypropylmethyl Cellulose (Boster Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's protocols.

    Detection of HMGB1 expression

    The serum samples of 15 liver failure patients with chronic HBV infection, 20 CHB patients and 10 healthy controls were isolated with routine methods, and stored in aliquots at -80 ℃ in microfuge tubes until assay. Serum HMGB1 levels were measured using the HMGB1 ELISA Kit II (Shino-Test Corp., Kanagawa, Japan) according to the manufacturer's recommendations. In brief, 10 μl of standards, and samples or controls supplemented with 100 μl diluent were added to the wells in microtiter plates, and incubated for 24 hours at 37 ℃. After washing, 100 μl/well of antihuman HMGB1 peroxidase-conjugated monoclonal antibody was added to the plates and incubated at room temperature for 2 hours. After washing, the chromogen 3, 3', 5, 5'-tetramethylbenzidine was added to each well to perform enzyme reaction for 30 minutes at room temperature before stopping by the addition of stop solution (0.35 mol/L Na2SO4). The absorbance was read at 450 nm, and the results were calculated using a calibration curve prepared from standards.

    HMGB1 mRNA levels in PBMC samples from enrolled patients and healthy controls were detected by real-time RT-PCR. Briefly, RNA was isolated from freshPBMCs using TRIzol reagent (Invitrogen Co., USA). Two micrograms total RNA was reverse-transcribed into cDNA using a random primer hexamer (Promega Corp., USA) and MultiScribeTMReverse Transcriptase (Applied Biosystems, USA). Gene expression was measured in real-time with the LightCycler (Roche, Switzerland) using primers and the QuantiTect SYBR green PCR Kit (Qiagen China Co., Ltd., Shanghai) according to the manufacturer's protocols. GAPDH was used as an internal control. The primers for HMGB1 were 5'-GCC TCC TTC GGC CTT CTT-3' and 5'-ACA GGC CAG GAT GTT CTC CTT T-3'; and for GAPDH were 5'-CCA CAT CGC TCA GAC ACC AT-3' and 5'-CCA GGC GCC CAA TAC G-3'. LightCycler collected data automatically and analyzed the value of threshold cycle (Ct). The fold change of HMGB1 mRNA expression in the patients with liver failure or CHB relative to control was detected using the 2-ΔΔCtmethod.[32]

    HMGB1 protein levels in liver tissues were assayed by Western blotting. Briefly, liver samples were obtained from enrolled patients and controls by percutaneous Menghini needle extraction. Samples (100 mg) were crushed in a liquid nitrogen-cooled grinding bowl and then lysed in cold RIPA buffer (Pierce Biotechnology, Inc., USA) supplemented with HaltTMProtease Inhibitor Cocktail (Pierce Biotechnology). Protein extracts (50 μg) were subjected to 12% SDS-PAGE and then transferred to a Protran? nitrocellulose membrane (Schleicher & Schuell BioScience GmbH, Germany). The membrane was incubated with a rabbit anti-HMGB1 primary antibody (Abcam plc., UK), then with a secondary goat anti-rabbit horseradish peroxidase-conjugated antibody (Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China), and finally assessed by chemiluminescence using the Enhanced NuGloTMChemiluminescent Substrate Kit (Alpha Diagnostic Intl. Inc., USA) followed by autoradiography and densitometric analysis. Membranes were also probed for β-actin as additional loading control.

    Flow cytometric analysis of CD4+CD25+CD127lowTreg cells

    PBMCs isolated from patients and controls were immediately frozen in RPMI-1640 (Gibco BRL, USA) containing 20% fetal calf serum (Gibco) and 10% dimethyl sulfoxide and stored at -135 ℃ until further use. PBMCs from different time points were tested simultaneously to avoid interassay variations in individual patients. The PBMCs (1×106) were incubated for 30 minutes at room temperature with fluorochromeconjugated antibodies specific for the surface markers CD4, CD25, and CD127 (anti-CD4-FITC, anti-CD25-PE-Cy5, and anti-CD127-PE, each 10 μl; BD Biosciences, USA). The cells were washed twice with phosphatebuffered saline (PBS), and made into a unicell suspension with a small amount of PBS. Flow cytometric analysis was performed using a FACSCaliburTMcytometer (BD Immunocytometry Systems, USA) as described elsewhere.[33,34]For CD25 and CD127 antibodies, isotypic matched control antibodies (IgG2a-PE-Cy5 and IgG1-PE; BD Biosciences) were used to determine the level of background staining. CD4+T cells were gated in PBMCs, and then CD25+CD127lowT lymphocytes, as a phenotype of Treg cells, were gated in CD4+T cells to analyze the proportion of Treg cells relative to CD4+T cells as described elsewhere.[35]

    Isolation of CD4+CD25+CD127lowTreg cells

    The PBMCs freshly isolated from CHB patients were enriched for CD4+T cells using a BD IMagTMHuman CD4 T Lymphocyte Enrichment Kit (BD Biosciences, USA). Briefly, a negative selection was performed using BD IMagTMstreptavidin particles with a cocktail of biotinylated monoclonal antibodies (mAbs) that recognizes antigens expressed on erythrocytes, platelets, granulocytes, monocytes, B cells, and CD8+T cells to enrich for the CD4+T lymphocytes. The CD4+T cells were then stained with fluorescence-labeled mAbs directed against human CD4, CD25, and CD127 (anti-CD4-FITC, anti-CD25-PE-Cy5, and anti-CD127-PE; BD Biosciences) for 30 minutes at 4 ℃. CD4+CD25+CD127lowand CD4+CD25lowCD127highsubsets were isolated using a BD FACSAriaTMcell sorter (BD Biosciences). The purity of FACS-sorted cell fractions was routinely 98%-99% for each T-cell fraction.

    Stimulation of Treg cells with HMGB1

    CD4+CD25+CD127lowTreg cells (1×106/ml) were seeded into 96-well plates coated with anti-CD3 (2 μg/ ml; Becton, Dickinson and Co., USA) in 10% FCS-RPMI 1640 complete culture medium (Gibco BRL, USA). Anti-CD28 (2 μg/ml; Becton, Dickinson and Company, USA) was added to the cells which were cultured for 24 hours, and then were stimulated with 100 μg/L HMGB1 for 12, 24, 36, or 48 hours, with various concentrations of HMGB1 (10, 50, 100, or 200 μg/L) for 24 hours. Every well had ten replicates and unstimulated cells were set as negative controls. Recombinant human HMGB1 was from Sigma-Aldrich Chemical Corp., USA at a greater purity more than 90%, dissolved in sterile PBS, and its concentration was confirmed by ELISA.

    Suppression assay

    A one-way mixed lymphocyte culture wasperformed in round-bottom 96-well microtiter plates. Briefly, 5×104CD4+CD25+CD127lowTreg cells treated with HMGB1 at different concentrations or at various intervals, 1×105autologous PBMCs from the same cell source as the CD4+CD25+CD127lowcells (responders), and 1×105allogeneic irradiated CD3-depleted PBMCs from a third party (stimulators) were incubated together for 7 days at 37 ℃ in 5% CO2. The allogeneic PBMCs were depleted of T cells using StemSep? Human CD3+T Cell Depletion (StemCell Technologies, Inc., Canada) according to the manufacturer's protocol and were irradiated with 40 Gy. Sixteen hours before the end of the incubation, 1 μCi3[H]-thymidine (Amersham GE, USA) was added to each well. Plates were harvested using a Tomtec? cell harvester (Tomtec Inc., USA) and3[H]-thymidine incorporation was measured using a MicroBeta? liquid scintillation counter (PerkinElmer Inc., USA), and the data were expressed as counts per minute (cpm). Experiments had ten replicates.

    Detection of forkhead box P3 (Foxp3) expression

    Foxp3 mRNA in Treg cells was detected by real-time RT-PCR. Briefly, RNA was isolated from CD4+CD25+CD127lowTreg cells stimulated with HMGB1 using TRIzol reagent. One microgram total RNA was reverse transcribed into cDNA using a random primer hexamer. Foxp3 mRNA expression was determined in real-time PCR with LightCycler using primers and a QuantiTect SYBR green PCR kit. The primers for Foxp3 were 5'-GAG AAG CTG AGT GCC ATG CA-3' and 5'-AGG AGC CCT TGT CGG ATG AT-3'. GAPDH served as an internal control. The 2-ΔΔCtmethod was used to analyze the fold change of Foxp3 mRNA expression relative to control.

    Foxp3 protein in Treg cells was assayed by Western blotting. Briefly, CD4+CD25+CD127lowTreg cells stimulated with HMGB1 (1×106/ml) were lysed in RIPA buffer supplemented with protease inhibitor. Protein extracts (50 μg) were subjected to 12% SDS-PAGE and then transferred to a Protran? nitrocellulose membrane. The membrane was incubated with a rabbit anti-Foxp3 primary antibody (Abcam plc., UK), and then with a secondary goat anti-rabbit horseradish peroxidaseconjugated antibody after washing in TBST, and finally detected by chemiluminescence using a commercial kit. β-actin was used as additional loading control.

    Statistical analysis

    All data are presented as mean±SEM. Calculations were performed with SPSS version 13.0 (SPSS, Chicago, IL, USA). Differences among groups were assessed by unpaired Student'sttest and one-way ANOVA. APvalue less than 0.05 was considered to be statistically significant.

    Results

    Higher expression of HMGB1 in liver failure patients

    To determine whether HMGB1 (a late inflammation mediator of endotoxemia) plays a role in the pathogenesis of liver failure caused by chronic HBV infection, the levels of HMGB1 in serum, PBMCs, and liver tissue from liver failure patients with chronic HBV infection, CHB patients, and healthy controls were evaluated by ELISA, real-time RT-PCR, and Western blotting. The results showed that the serum HMGB1 levels were 82.6±20.1 μg/L in liver failure patients, 34.2± 13.7 μg/L in CHB patients, and 27.8±6.5 μg/L in healthy controls. Serum HMGB1 levels were greater in the liver failure patients than in the CHB patients (t=8.48,P<0.01), and the serum HMGB1 levels did not differ between the CHB patients and healthy controls (t=1.73,P>0.05) (Fig. 1A). The results of RT-PCR and Western blotting furtherconfirmed a higher expression of HMGB1 mRNA in PBMCs and HMGB1 protein in the liver tissues of the liver failure patients than in the CHB patients (5.21±0.42 vs. 1.78±0.18,t=29.43,P<0.01; 4.86±1.07 vs. 1.43±0.35,t=13.46,P<0.01, respectively). HMGB1 expression levels of CHB patients were higher than healthy controls, but the difference was not statistically significant (Fig. 1B and 1C).

    Fig. 1. HMGB1 levels in liver failure patients with chronic HBV infection. A: Serum HMGB1 levels detected by ELISA in liver failure patients with chronic HBV infection, CHB patients, and healthy controls. B: HMGB1 mRNA expression levels in PBMCs analyzed by real-time RT-PCR (graph) in enrolled patients and healthy controls, and a representative RT-PCR specific for HMGB1 and GAPDH (internal control) are shown in the upper panel. C: HMGB1 protein expression levels in liver tissue analyzed by Western blotting in enrolled patients and healthy controls. 1: healthy controls; 2: CHB patients; 3: liver failure patients with chronic HBV infection. *: P<0.01, compared with CHB patients.

    Fig. 2. Percentage of CD4+CD25+CD127lowTreg cells within the CD4+cell fraction in liver failure patients with chronic HBV infection. A-C: Typical dot plots obtained by flow cytometry using antibodies against CD4, CD25, CD127 from a representative liver failure patient, a representative CHB patient, and a representative healthy control respectively. CD4+T cells were gated in PBMCs, and then CD25+CD127lowT lymphocytes, a phenotype of Treg cells, were gated in CD4+T cells to analyze the proportion of Treg cells relative to CD4+T cells. D: CHB patients showed a higher percentage of Treg cells within their population of CD4+T cells in PBMCs compared with healthy controls, while liver failure patients with chronic HBV infection showed a decreased proportion of Treg cells relative to CD4+T cells compared with CHB patients. Bar represents median percentage of Tregs.

    Fig. 3. Suppression assay of allogeneic MLR. 5×104CD4+CD25+CD127lowTreg cells treated with HMGB1 at different concentrations or at various intervals were combined with 1×105autologous PBMCs as responders, and 1×105allogeneic anti-CD3 depleted, irradiated third-party PBMCs as stimulators and incubated together for 7 days at 37 ℃ in 5%CO2. Sixteen hours before the end of incubation, 1 μCi3[H]-thymidine was added to each well. Plates were harvested and data was detected using a liquid scintillation counter. The results are presented as counts per minute (cpm), and showed that the ability of CD4+CD25+CD127lowTreg cells to suppress an allogeneic MLR was significantly weakened after treatment with HMGB1 compared with untreated Treg cells. Moreover, the reduced ability of Treg cells to suppress the MLR was related to HMGB1 treatment in a dose- and time-dependent manner.

    Lower proportion of Treg cells in liver failure patients

    Recently, a novel combined panel of biomarkers, CD4+CD25+CD127low, was confirmed by intracellular staining of Foxp3 antigen to be effective in identifying Treg cells.[36]To investigate the roles of Treg cells in the pathogenesis of liver failure caused by chronic HBV infection, the percentage of CD4+CD25+CD127lowTreg cells within the CD4+cell fraction among the PBMCs from liver failure patients with chronic HBV infection, CHB patients, and healthy controls was determined by this novel flow-cytometric approach. Representative dot plots obtained by flow cytometry from enrolled patients and healthy controls are shown in Fig. 2A-C. CHBpatients had a higher percentage of Treg cells within their population of CD4+T cells in PBMCs than healthy controls (9.52±3.89% vs. 3.21±1.21%,t=4.97,P<0.01; Fig. 2D). But in liver failure patients with chronic HBV infection, a decreased proportion of Treg cells relative to CD4+T cells was found compared with CHB patients (4.55±1.34% vs. 9.52±3.89%,t=4.73,P<0.01).

    Fig. 4. Changes of Foxp3 expression after stimulating Treg cells with HMGB1. *: P<0.01, compared with 12 hours; ▲: P>0.05, #: P<0.01, compared with 10 μg/L. A: RT-PCR results for Foxp3 mRNA in Treg cells treated with HMGB1 at various intervals or at different concentrations. B: Detection of Foxp3 mRNA in Treg cells treated with 100 μg/L HMGB1 for 12, 24, 36 and 48 hours by real-time RTPCR. Untreated Treg cells highly expressed Foxp3 mRNA, while in Treg cells treated with HMGB1, this expression was significantly down-regulated at 12 hours to 48 hours, and the levels were lowest at 48 hours. C: Detection of Foxp3 mRNA in Treg cells treated with various concentrations of HMGB1 (10, 50, 100 and 200 μg/L) for 24 hours by real-time RT-PCR. Compared with untreated Treg cells, the Foxp3 mRNA expression were significantly down-regulated in Treg cells treated with various concentration of HMGB1, and the expression levels of Foxp3 mRNA were lowest at 200 μg/L. D-F: Assay of Foxp3 protein by Western blotting in Treg cells treated with HMGB1. Foxp3 protein levels were decreased in a dose- or time-dependent manner, when Treg cells were treated with HMGB1 in vitro.

    HMGB1 inhibits Treg cells immune activity

    To determine whether HMGB1 affects Treg cell activity, a suppression assay of allogeneic mixed lymphocyte response (MLR) was performed using CD4+CD25+CD127lowTreg cells isolated from the PBMCs of CHB patients and treated with HMGB1 at different concentrations or at various intervals to determine the changes of their ability to suppress T-cell proliferation. The ability of CD4+CD25+CD127lowTreg cells to suppress an allogeneic MLR was significantly weakened after treatment with HMGB1 compared with untreated Treg cells (Fig. 3). Moreover, reduction of the ability of Treg cells to suppress the MLR was related to HMGB1 treatment in a dose- and time-dependent manner. The results suggested that HMGB1 effectively inhibits the immune activity of Treg cells.

    Down-regulation of Foxp3 expression in Treg cells treated with HMGB1

    To explore whether HMGB1 affects Foxp3 expression in Treg cells and thereby weakens their immune activity, we assessed the changes of Foxp3 expression in Treg cells treated with HMGB1 at different concentrations or at various intervals by real-time RT-PCR and Western blotting. The results demonstrated that untreated Treg cells highly expressed Foxp3 mRNA and protein, while the expression levels were significantly down-regulated in Treg cells after treatment with 100 μg/L HMGB1 for 12 to 48 hours (0.86±0.10, 0.52±0.14, 0.37±0.09, and 0.21±0.04, respectively for mRNA; 0.92±0.08, 0.63± 0.11, 0.42±0.07, and 0.29±0.02, respectively for protein). The Foxp3 expression levels were the lowest at 48 hours. When Tregs were stimulated with various concentrations of HMGB1 (10, 50, 100, and 200 μg/L) for 24 hours, the Foxp3 expression was also significantly decreased (0.91± 0.04, 0.80±0.09, 0.61±0.13, and 0.42±0.06, respectively for mRNA; 0.89±0.06, 0.74±0.11, 0.62±0.08, and 0.35± 0.07, respectively for protein), and the expression levels were the lowest at 200 μg/L HMGB1 (Fig. 4).

    Discussion

    Liver failure caused by chronic HBV infection is a severe life-threatening condition, the pathogenesis of which is complex and still not entirely clear. Some believethat liver failure is related to "primary liver injury" induced directly or indirectly (i.e. immunopathological damage) by HBV and "secondary liver injury” induced by intestinal endotoxemia and the activation of Kupffer cells by endotoxin (LPS) with the progress of liver disease.[6]Intestinal endotoxemia results from overgrowth and translocation of gram-negative bacteria from the gut to the peritoneal cavity because of the increased permeability of the intestinal wall, which leads to spontaneous peritonitis and so plays a significant role in the progress of liver failure.[7,8]Recently, it has been shown that HMGB1 protein, a late inflammatory mediator, is involved in the processes of endotoxemia, and is a successful therapeutic target in diverse inflammatory and infectious disorders.[10,11]In the present study, we assessed the levels of HMGB1 in serum, PBMCs, and liver tissue from liver failure patients with chronic HBV infection, and found that serum HMGB1 levels were significantly greater in liver failure patients than in CHB patients (82.6±20.1 μg/L vs. 34.2±13.7 μg/L), and that there were no significant differences in serum HMGB1 levels between CHB patients and healthy controls. The results of RT-PCR and Western blotting further confirmed significantly higher expression of HMGB1 mRNA in PBMCs and HMGB1 protein in the liver tissues of liver failure patients than in those of CHB patients and healthy controls. It is suggested that HMGB1 is involved in the pathogenesis of liver failure caused by chronic HBV infection.

    Previous studies have demonstrated that Treg cells play an essential role in maintaining immune tolerance and contributing to immunological hyporesponsiveness against HBV infection,[27-30]suggesting that Treg cells limit liver injury by controlling inflammation and reduce the incidence of liver failure simultaneously, and maintain persistent HBV infection by suppressing the immune response. However, the roles of Treg cells in the pathogenesis of liver failure in CHB patients are poorly known at present. For this reason, in our study, the percentage changes of CD4+CD25+CD127lowT cells, a novel combined panel of biomarkers for identifying Treg cells effectively,[36]were determined within the CD4+T cell fraction among the PBMCs from liver failure patients with chronic HBV infection, CHB patients, and healthy controls by a flow-cytometric approach. Currently, the most definitive marker for identification of Treg cells is the Foxp3 transcription factor.[37-39]However, identification of intracellular Foxp3 requires permeabilization of the cells, making it difficult to work with or culture the cells again once the staining is complete. Recently, a combination of monoclonal antibodies against CD4, CD25 (the α chain of the IL-2 receptor), and CD127 (the α chain of the IL-7 receptor) was used for flow cytometry-based delineation of a wellseparated CD4+CD25+CD127lowpopulation of putative Treg cells, which had the most highly suppressive ability in functional assays, a poor response to T-cell receptor signaling, and the highest levels of Foxp3 compared with other cell subsets.[35,36,40,41]We found that CHB patients had a significantly higher percentage of Treg cells within their population of CD4+T cells in PBMCs than healthy controls (9.52±3.89% vs. 3.21± 1.21%). However, liver failure patients with chronic HBV infection had a significantly decreased proportion of Treg cells within their population of CD4+T cells in PBMCs compared with CHB patients (4.55±1.34% vs. 9.52±3.89%). These results suggested that downregulation of Treg cells occurs in liver failure patients with chronic HBV infection, which can aggravate liver injury by enhancing the immunological responsiveness to HBV, thereby resulting in liver failure in chronic HBV infection. Therefore, down-regulation of Treg cells may play a significant role in the pathogenesis of liver failure in CHB patients.

    Since we found that higher levels of HMGB1 and a lower percentage of Treg cells were both present in liver failure patients, whether HMGB1 affects Treg cell activity in liver failure patients is a question. To answer this, a suppression assay of allogeneic MLR was performed using CD4+CD25+CD127lowTreg cells isolated from the PBMCs of CHB patients and treated with HMGB1 at different concentrations or at various intervals to determine the changes of their ability to suppress T cell proliferation. We found that this ability was significantly weakened after treatment with HMGB1 compared with untreated Treg cells. Moreover, the reduced ability of Treg cells to suppress the MLR was related to HMGB1 treatment in a dose- and timedependent manner. The results suggested that HMGB1 effectively inhibits the immune activity of Treg cells in liver failure patients, which may be a reason for downregulation of Treg cells in such patients with high levels of HMGB1.

    In the present study, to preliminarily explore the mechanism of the weakening of immune activity of Treg cells induced by HMGB1, the changes of Foxp3 expression were assessed in Treg cells treated with HMGB1 at different concentrations and at various intervals by real-time RT-PCR and Western blotting. The results demonstrated that untreated Treg cells highly expressed Foxp3, while the Foxp3 expression was significantly down-regulated after treatment with HMGB1 in a dose- and time-dependent manner. Foxp3 is a transcription factor specifically expressedby Treg cells, and the levels of Foxp3 gene expression directly reflect the phenotype and activity of Tregs.[39]Therefore, it is suggested that HMGB1 weakens the immune activity of Treg cells probably by reducing their expression of Foxp3.

    Although advances in intensive care management and liver transplantation have improved the survival of liver failure patients, the prognosis of liver failure in CHB patients remains poor. Therefore, it is especially important to explore more effective interventions for the management of liver failure in these patients. In this study, the results showed that a high level of HMGB1, a late inflammatory mediator of endotoxemia, plays an important role in the pathogenesis of liver failure in CHB patients by inhibiting the immune activity of Treg cells. It is suggested that HMGB1 antagonists are a feasible way to treat liver failure by suppression of endotoxemia and have protective effects on liver damage as well as the activity of Treg cells. On the other hand, immuno-modulation therapy is also a potential intervention for liver failure in CHB patients. This hypothesis awaits further study.

    Funding:This study was supported by a grant from the National Natural Science Foundation of China (No. 81071342).

    Ethical approval:The study was approved by the Renmin Hospital of Wuhan University Medical Ethics Committee.

    Contributors:WLW and GZJ proposed the study. WLW wrote the first draft. WLW and CH analyzed the data. All authors contributed to the design and interpretation of the study and to further drafts. GZJ is the guarantor.

    Competing interest:No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    1 Pappas G, Papadimitriou P, Falagas ME. World Wide Web hepatitis B virus resources. J Clin Virol 2007;38:161-164.

    2 Zou L, Zhang W, Ruan S. Modeling the transmission dynamics and control of hepatitis B virus in China. J Theor Biol 2010;262:330-338.

    3 Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect 2009;58:383-388.

    4 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22:5-13.

    5 Chen C, Li L, Wu Z, Chen H, Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect 2007;54:98-102.

    6 Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol 2002;8:961-965.

    7 Li L, Wu Z, Ma W, Yu Y, Chen Y. Changes in intestinal microflora in patients with chronic severe hepatitis. Chin Med J (Engl) 2001;114:869-872.

    8 Sozinov AS. Systemic endotoxemia during chronic viral hepatitis. Bull Exp Biol Med 2002;133:153-155.

    9 Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.

    10 Tang Y, Lv B, Wang H, Xiao X, Zuo X. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol 2008;8:1646-1651.

    11 Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149-156.

    12 Ditsworth D, Zong WX, Thompson CB. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 2007;282:17845-17854.

    13 Lange SS, Vasquez KM. HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol Carcinog 2009;48:571-580.

    14 Ugrinova I, Pashev IG, Pasheva EA. Post-synthetic acetylation of HMGB1 protein modulates its interactions with supercoiled DNA. Mol Biol Rep 2009;36:1399-1404.

    15 Assenberg R, Webb M, Connolly E, Stott K, Watson M, Hobbs J, et al. A critical role in structure-specific DNA binding for the acetylatable lysine residues in HMGB1. Biochem J 2008;411:553-561.

    16 Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008;180:2531-2537.

    17 Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007;81:49-58.

    18 Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61:1-9.

    19 Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135-1143.

    20 Feng Y, Yang Q, Xu J, Qian G, Liu Y. Effects of HMGB1 on PMN apoptosis during LPS-induced acute lung injury. Exp Mol Pathol 2008;85:214-222.

    21 Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, et al. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007;13:210-215.

    22 Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009;32: 348-357.

    23 Livesey KM, Tang D, Zeh HJ, Lotze MT. Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1. Curr Opin Investig Drugs 2008;9:1259-1263.

    24 Sakaguchi S, Wing K, Miyara M. Regulatory T cells-a brief history and perspective. Eur J Immunol 2007;37:S116-123.

    25 Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression-a diverse arsenal for a moving target. Immunology 2008;124:13-22.

    26 Tang Q, Bluestone JA. The Foxp3+regulatory T cell: a jackof all trades, master of regulation. Nat Immunol 2008;9:239-244.

    27 Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771-778.

    28 Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, et al. Modulation of the CD8+-T-cell response by CD4+CD25+regulatory T cells in patients with hepatitis B virus infection. J Virol 2005;79:3322-3328.

    29 Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007;361:141-148.

    30 Feng IC, Koay LB, Sheu MJ, Kuo HT, Sun CS, Lee C, et al. HBcAg-specific CD4+CD25+regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J Biomed Sci 2007;14:43-57.

    31 Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi 2006;14:643-646.

    32 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.

    33 Moniuszko M, Edghill-Smith Y, Venzon D, Stevceva L, Nacsa J, Tryniszewska E, et al. Decreased number of CD4+and CD8+T cells that express the interleukin-7 receptor in blood and tissues of SIV-infected macaques. Virology 2006;356:188-197.

    34 Moniuszko M, Kowal K, Rusak M, Pietruczuk M, Dabrowska M, Bodzenta-Lukaszyk A. Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples: influence of different anticoagulants. Clin Vaccine Immunol 2006;13:704-707.

    35 Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-1700.

    36 Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells. J Exp Med 2006;203:1701-1711.

    37 Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005;6:331-337.

    38 Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-352.

    39 Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-341.

    40 Hartigan-O'Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007;319:41-52.

    41 Moniuszko M, Kowal K, Zukowski S, Dabrowska M, Bodzenta-Lukaszyk A. Frequencies of circulating CD4+CD25+CD127low cells in atopics are altered by bronchial allergen challenge. Eur J Clin Invest 2008;38:201-204.

    March 23, 2010

    Accepted after revision May 5, 2010

    Author Affiliations: Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China (Wang LW, Chen H and Gong ZJ)

    Zuo-Jiong Gong, MD, PhD, Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China (Tel: 86-27-88041911ext88385; Fax: 86-27-88042292; Email: zjgong@163.com)

    ? 2010, Hepatobiliary Pancreat Dis Int. All rights reserved.

    久久人人爽人人片av| 国产精华一区二区三区| 亚洲成人中文字幕在线播放| 国内精品一区二区在线观看| 97超碰精品成人国产| 亚洲欧美日韩东京热| 一个人看视频在线观看www免费| 精品久久久噜噜| 国产乱人偷精品视频| 能在线免费观看的黄片| 一区二区三区乱码不卡18| 1024手机看黄色片| 少妇人妻精品综合一区二区| 亚洲精华国产精华液的使用体验| 亚洲精品,欧美精品| 亚洲精品成人久久久久久| av在线天堂中文字幕| 免费黄色在线免费观看| 国产伦理片在线播放av一区| 国产精品无大码| 日韩强制内射视频| 欧美丝袜亚洲另类| 丝袜喷水一区| 国产爱豆传媒在线观看| 狂野欧美激情性xxxx在线观看| 亚洲国产色片| 亚洲精华国产精华液的使用体验| 久久国产乱子免费精品| 免费搜索国产男女视频| 日韩欧美国产在线观看| 日韩欧美 国产精品| 久久久久久久久久黄片| av女优亚洲男人天堂| 久久久久久久亚洲中文字幕| 久久久久久九九精品二区国产| 亚洲久久久久久中文字幕| 两性午夜刺激爽爽歪歪视频在线观看| 欧美日韩精品成人综合77777| 国产淫片久久久久久久久| 中文字幕精品亚洲无线码一区| 成人美女网站在线观看视频| 日本免费一区二区三区高清不卡| 国产高清国产精品国产三级 | 日韩成人伦理影院| 亚洲欧美精品专区久久| 视频中文字幕在线观看| 又爽又黄无遮挡网站| 亚洲经典国产精华液单| 国产高潮美女av| 久久国产乱子免费精品| АⅤ资源中文在线天堂| 中国国产av一级| 色播亚洲综合网| 99久国产av精品国产电影| 久久久国产成人精品二区| 尤物成人国产欧美一区二区三区| 国产午夜精品一二区理论片| 久久久久久久久久久免费av| ponron亚洲| 国产一区二区在线观看日韩| 一边摸一边抽搐一进一小说| 啦啦啦观看免费观看视频高清| 麻豆久久精品国产亚洲av| 国产精品一区二区三区四区久久| 精品欧美国产一区二区三| 一级爰片在线观看| 两个人的视频大全免费| 狂野欧美激情性xxxx在线观看| 秋霞在线观看毛片| 欧美激情久久久久久爽电影| 日韩大片免费观看网站 | 看黄色毛片网站| 日韩精品青青久久久久久| 成人特级av手机在线观看| 亚洲成人久久爱视频| 国产激情偷乱视频一区二区| 亚洲精品久久久久久婷婷小说 | 男女那种视频在线观看| 午夜福利高清视频| 偷拍熟女少妇极品色| 国产精品国产三级国产专区5o | 一边摸一边抽搐一进一小说| 午夜激情欧美在线| 国产在视频线在精品| 国产淫语在线视频| 亚洲经典国产精华液单| 日韩成人伦理影院| 国产成人a∨麻豆精品| 日韩亚洲欧美综合| 少妇人妻精品综合一区二区| 女的被弄到高潮叫床怎么办| 欧美成人精品欧美一级黄| 国产av不卡久久| 国产男人的电影天堂91| 一级毛片aaaaaa免费看小| 成人一区二区视频在线观看| 国模一区二区三区四区视频| 两性午夜刺激爽爽歪歪视频在线观看| 国产淫语在线视频| 男人的好看免费观看在线视频| 中文字幕制服av| 欧美人与善性xxx| 国产三级中文精品| 我的女老师完整版在线观看| 高清av免费在线| 国产在线男女| 精品国产露脸久久av麻豆 | 三级毛片av免费| 久久99热这里只有精品18| 免费看a级黄色片| 亚洲美女视频黄频| 日本三级黄在线观看| 内地一区二区视频在线| 成人美女网站在线观看视频| 国产精品日韩av在线免费观看| 少妇丰满av| 五月玫瑰六月丁香| 亚洲美女视频黄频| 日韩欧美精品v在线| av在线观看视频网站免费| 男女下面进入的视频免费午夜| 91午夜精品亚洲一区二区三区| 人人妻人人澡欧美一区二区| 99久久精品热视频| 欧美性猛交╳xxx乱大交人| 日韩高清综合在线| 午夜激情欧美在线| 老女人水多毛片| 日韩一区二区视频免费看| 两性午夜刺激爽爽歪歪视频在线观看| 网址你懂的国产日韩在线| 小说图片视频综合网站| 在线观看av片永久免费下载| 欧美区成人在线视频| 国产乱人视频| 久久精品人妻少妇| 欧美又色又爽又黄视频| 69人妻影院| 亚洲不卡免费看| 欧美日韩一区二区视频在线观看视频在线 | 性插视频无遮挡在线免费观看| 嫩草影院入口| a级毛片免费高清观看在线播放| 我要看日韩黄色一级片| 国产片特级美女逼逼视频| 国产激情偷乱视频一区二区| 久久99蜜桃精品久久| 亚洲av福利一区| 床上黄色一级片| 国产成年人精品一区二区| av在线天堂中文字幕| 晚上一个人看的免费电影| 精品国产一区二区三区久久久樱花 | 国产亚洲最大av| 欧美3d第一页| 亚洲中文字幕一区二区三区有码在线看| 国产男人的电影天堂91| 18禁动态无遮挡网站| 在线天堂最新版资源| 亚洲欧洲日产国产| 中文字幕免费在线视频6| 插逼视频在线观看| 亚洲怡红院男人天堂| 日韩大片免费观看网站 | 噜噜噜噜噜久久久久久91| 成年女人永久免费观看视频| 99久久无色码亚洲精品果冻| 在线免费观看不下载黄p国产| 尤物成人国产欧美一区二区三区| 国产精品99久久久久久久久| 久久久久久九九精品二区国产| 国产午夜精品久久久久久一区二区三区| 午夜福利高清视频| 亚洲精品久久久久久婷婷小说 | 九色成人免费人妻av| 99久久中文字幕三级久久日本| 一边亲一边摸免费视频| 欧美极品一区二区三区四区| 国产爱豆传媒在线观看| 国模一区二区三区四区视频| 麻豆成人av视频| 菩萨蛮人人尽说江南好唐韦庄 | 欧美最新免费一区二区三区| 激情 狠狠 欧美| 99热这里只有精品一区| 亚洲激情五月婷婷啪啪| 午夜老司机福利剧场| 国产精品野战在线观看| 亚洲伊人久久精品综合 | 欧美日韩综合久久久久久| 少妇的逼好多水| 99久国产av精品| 你懂的网址亚洲精品在线观看 | 免费无遮挡裸体视频| 欧美精品国产亚洲| 亚洲图色成人| 日本与韩国留学比较| 日韩欧美精品免费久久| 精品少妇黑人巨大在线播放 | 少妇的逼水好多| 久久99蜜桃精品久久| 国产视频首页在线观看| 国产又黄又爽又无遮挡在线| 精品人妻视频免费看| 免费观看的影片在线观看| 亚洲欧美成人精品一区二区| 国产成年人精品一区二区| 成人鲁丝片一二三区免费| 精品国产露脸久久av麻豆 | 六月丁香七月| 尾随美女入室| 久久精品影院6| 极品教师在线视频| www.av在线官网国产| 汤姆久久久久久久影院中文字幕 | 欧美变态另类bdsm刘玥| 欧美人与善性xxx| 久久久午夜欧美精品| 国产成年人精品一区二区| 18禁在线播放成人免费| 国产视频首页在线观看| 久久99热这里只频精品6学生 | 国产又色又爽无遮挡免| 身体一侧抽搐| 亚洲av成人av| 中文字幕免费在线视频6| 欧美一区二区精品小视频在线| 欧美zozozo另类| 欧美潮喷喷水| 丰满人妻一区二区三区视频av| 麻豆精品久久久久久蜜桃| 人体艺术视频欧美日本| 成人午夜高清在线视频| 亚洲欧美成人精品一区二区| 国产av不卡久久| 久久久久久久国产电影| 国产精品福利在线免费观看| 亚洲欧美一区二区三区国产| 亚洲欧美精品自产自拍| 天天躁日日操中文字幕| 伦精品一区二区三区| 五月玫瑰六月丁香| 日韩欧美国产在线观看| 精品国产三级普通话版| 久久久国产成人精品二区| av在线蜜桃| 91精品伊人久久大香线蕉| 国产成人午夜福利电影在线观看| 亚洲av成人av| 丝袜喷水一区| 久久精品夜夜夜夜夜久久蜜豆| 国产黄色视频一区二区在线观看 | 亚洲国产精品成人久久小说| 全区人妻精品视频| 嫩草影院入口| 大香蕉久久网| 嫩草影院新地址| 久久这里有精品视频免费| 亚洲国产精品专区欧美| 亚洲av电影不卡..在线观看| 美女大奶头视频| 国产精品一区www在线观看| 一个人看的www免费观看视频| 日韩强制内射视频| 成人欧美大片| 国产国拍精品亚洲av在线观看| 亚洲人成网站在线播| 神马国产精品三级电影在线观看| 亚洲欧美中文字幕日韩二区| 日本黄大片高清| 嫩草影院入口| 女人久久www免费人成看片 | 亚洲国产日韩欧美精品在线观看| 精品人妻视频免费看| 91aial.com中文字幕在线观看| a级毛片免费高清观看在线播放| 好男人在线观看高清免费视频| 麻豆一二三区av精品| av播播在线观看一区| 两个人视频免费观看高清| 中文在线观看免费www的网站| 日韩欧美 国产精品| 欧美成人a在线观看| 中文资源天堂在线| 国产精品爽爽va在线观看网站| 中文字幕免费在线视频6| 我的老师免费观看完整版| av在线天堂中文字幕| 亚洲国产精品久久男人天堂| 国产成人精品久久久久久| 国产精品人妻久久久影院| 亚洲欧美中文字幕日韩二区| 亚洲国产日韩欧美精品在线观看| 精华霜和精华液先用哪个| 国语对白做爰xxxⅹ性视频网站| 秋霞伦理黄片| 久久精品影院6| 国产综合懂色| 美女国产视频在线观看| 尤物成人国产欧美一区二区三区| 热99在线观看视频| 亚洲美女搞黄在线观看| 午夜a级毛片| 免费看av在线观看网站| 亚洲成人精品中文字幕电影| 国产精品久久久久久久久免| 国内精品美女久久久久久| 午夜福利在线观看吧| 不卡视频在线观看欧美| 午夜亚洲福利在线播放| 国产精品99久久久久久久久| 国产黄色小视频在线观看| 国产成人午夜福利电影在线观看| 久久久久久久午夜电影| 波多野结衣巨乳人妻| АⅤ资源中文在线天堂| 欧美潮喷喷水| 久久精品综合一区二区三区| 成人午夜精彩视频在线观看| 变态另类丝袜制服| 免费人成在线观看视频色| 免费电影在线观看免费观看| 青春草国产在线视频| 久久久久久久久久久免费av| 少妇猛男粗大的猛烈进出视频 | 免费观看在线日韩| 禁无遮挡网站| 身体一侧抽搐| 成人性生交大片免费视频hd| 天天躁夜夜躁狠狠久久av| 久久久久网色| 一区二区三区高清视频在线| 久久久久网色| 日本免费一区二区三区高清不卡| 久久精品夜色国产| 亚洲精品日韩在线中文字幕| 国产精品国产三级国产专区5o | 欧美成人午夜免费资源| 热99在线观看视频| 精品久久久久久久久久久久久| 少妇丰满av| 久热久热在线精品观看| eeuss影院久久| 婷婷色av中文字幕| 亚洲精品日韩av片在线观看| 国产精品久久久久久久久免| 久久精品久久久久久噜噜老黄 | 国产成人精品婷婷| 啦啦啦观看免费观看视频高清| 亚洲自偷自拍三级| 国产精品永久免费网站| 99久久精品热视频| 观看免费一级毛片| 五月玫瑰六月丁香| 久久精品熟女亚洲av麻豆精品 | 搡老妇女老女人老熟妇| 人妻制服诱惑在线中文字幕| 欧美成人a在线观看| 网址你懂的国产日韩在线| 色播亚洲综合网| 99久久九九国产精品国产免费| 久久99热这里只频精品6学生 | 国产一级毛片在线| 少妇被粗大猛烈的视频| 久热久热在线精品观看| 精品国产三级普通话版| 天堂影院成人在线观看| 亚州av有码| 亚洲在线自拍视频| 变态另类丝袜制服| 免费av观看视频| 狂野欧美激情性xxxx在线观看| 国产又色又爽无遮挡免| 亚洲av一区综合| 熟妇人妻久久中文字幕3abv| 精品免费久久久久久久清纯| 成年版毛片免费区| 亚洲综合精品二区| 国产女主播在线喷水免费视频网站 | 国产黄片视频在线免费观看| 亚洲欧美日韩东京热| 一个人免费在线观看电影| 国产成人freesex在线| 国产黄片视频在线免费观看| 一个人看的www免费观看视频| 一个人观看的视频www高清免费观看| 女人久久www免费人成看片 | 久久久午夜欧美精品| 日韩一区二区三区影片| 亚洲欧美日韩无卡精品| 中文字幕制服av| 亚洲欧洲国产日韩| 国产大屁股一区二区在线视频| 美女黄网站色视频| 91精品国产九色| 欧美三级亚洲精品| 91久久精品电影网| 丝袜美腿在线中文| 欧美高清成人免费视频www| 日韩制服骚丝袜av| 亚洲一区高清亚洲精品| av在线蜜桃| 国产亚洲精品久久久com| 两性午夜刺激爽爽歪歪视频在线观看| 国产亚洲午夜精品一区二区久久 | 国产精品久久久久久精品电影| 午夜爱爱视频在线播放| 人体艺术视频欧美日本| 亚洲av一区综合| 日韩一区二区视频免费看| 久久99热这里只有精品18| 免费看av在线观看网站| 91久久精品电影网| 国产亚洲av嫩草精品影院| 三级经典国产精品| 一级毛片久久久久久久久女| 欧美潮喷喷水| 亚洲精品色激情综合| 国产精品蜜桃在线观看| 少妇丰满av| 国产乱人偷精品视频| 日韩三级伦理在线观看| 中文字幕av在线有码专区| 国产精品精品国产色婷婷| 国产成人freesex在线| 毛片一级片免费看久久久久| 欧美日韩一区二区视频在线观看视频在线 | 国产精品国产高清国产av| 欧美zozozo另类| 夫妻性生交免费视频一级片| 国产精品熟女久久久久浪| 国内少妇人妻偷人精品xxx网站| 麻豆乱淫一区二区| 久久精品久久久久久噜噜老黄 | or卡值多少钱| 亚洲人成网站高清观看| 国产成人91sexporn| 狂野欧美白嫩少妇大欣赏| 最近中文字幕高清免费大全6| av在线老鸭窝| 热99在线观看视频| 精品人妻熟女av久视频| 在线播放无遮挡| 亚洲综合色惰| 国产精品伦人一区二区| 亚洲精品aⅴ在线观看| 最后的刺客免费高清国语| 日本av手机在线免费观看| 菩萨蛮人人尽说江南好唐韦庄 | 免费在线观看成人毛片| 日本黄大片高清| 一个人观看的视频www高清免费观看| 高清视频免费观看一区二区 | 搡老妇女老女人老熟妇| 久久亚洲国产成人精品v| 亚洲内射少妇av| 天堂网av新在线| 国产精品av视频在线免费观看| 麻豆精品久久久久久蜜桃| 亚洲精品久久久久久婷婷小说 | 看十八女毛片水多多多| 少妇猛男粗大的猛烈进出视频 | 免费看av在线观看网站| 久久热精品热| 国产精品嫩草影院av在线观看| 一个人看视频在线观看www免费| av在线天堂中文字幕| 国产伦一二天堂av在线观看| 日本猛色少妇xxxxx猛交久久| 最近最新中文字幕大全电影3| 精品人妻一区二区三区麻豆| av国产免费在线观看| 成人二区视频| 中文欧美无线码| 干丝袜人妻中文字幕| 人人妻人人澡欧美一区二区| 亚洲欧美中文字幕日韩二区| 久久精品91蜜桃| 18禁在线无遮挡免费观看视频| 成年版毛片免费区| 亚洲aⅴ乱码一区二区在线播放| 日日摸夜夜添夜夜添av毛片| 九九热线精品视视频播放| 丝袜喷水一区| 久久国产乱子免费精品| 热99re8久久精品国产| 最近中文字幕2019免费版| 综合色丁香网| 麻豆一二三区av精品| 99在线人妻在线中文字幕| 观看免费一级毛片| 国产私拍福利视频在线观看| 亚洲精品一区蜜桃| 免费av毛片视频| 国产精品久久电影中文字幕| 日韩欧美三级三区| 尾随美女入室| 国语对白做爰xxxⅹ性视频网站| 又粗又爽又猛毛片免费看| 亚洲av电影不卡..在线观看| 久久人人爽人人爽人人片va| 国产成人freesex在线| 午夜福利视频1000在线观看| 国产亚洲5aaaaa淫片| 色尼玛亚洲综合影院| 国产精品日韩av在线免费观看| 九草在线视频观看| 亚洲国产色片| 欧美bdsm另类| 亚洲丝袜综合中文字幕| 日日干狠狠操夜夜爽| 国产一级毛片七仙女欲春2| 热99re8久久精品国产| 成人国产麻豆网| 精品国内亚洲2022精品成人| 日韩成人av中文字幕在线观看| 全区人妻精品视频| 国产69精品久久久久777片| 久久久久久伊人网av| 少妇的逼水好多| 性插视频无遮挡在线免费观看| 日本免费一区二区三区高清不卡| 99热这里只有精品一区| 麻豆国产97在线/欧美| 黄色一级大片看看| 乱系列少妇在线播放| 在线观看一区二区三区| 国产伦精品一区二区三区四那| 日韩av在线大香蕉| 久久久亚洲精品成人影院| 中文字幕免费在线视频6| 变态另类丝袜制服| 白带黄色成豆腐渣| 最近的中文字幕免费完整| 久久这里只有精品中国| 国产又色又爽无遮挡免| 能在线免费看毛片的网站| 汤姆久久久久久久影院中文字幕 | 国产精品野战在线观看| 毛片一级片免费看久久久久| 男人舔奶头视频| 亚洲精品乱码久久久v下载方式| 色哟哟·www| 成年版毛片免费区| 午夜激情福利司机影院| 亚洲伊人久久精品综合 | 国产亚洲5aaaaa淫片| 女的被弄到高潮叫床怎么办| 免费电影在线观看免费观看| 欧美变态另类bdsm刘玥| 亚洲欧美日韩卡通动漫| 天堂中文最新版在线下载 | 国产伦精品一区二区三区视频9| 午夜精品一区二区三区免费看| 中国国产av一级| 黄色日韩在线| 国产真实乱freesex| 国产真实伦视频高清在线观看| 国产久久久一区二区三区| 国产亚洲91精品色在线| 麻豆成人av视频| 性色avwww在线观看| 22中文网久久字幕| 免费看日本二区| 99久久中文字幕三级久久日本| 波多野结衣巨乳人妻| 亚洲aⅴ乱码一区二区在线播放| 国产一级毛片七仙女欲春2| 韩国高清视频一区二区三区| 亚洲美女视频黄频| av专区在线播放| 视频中文字幕在线观看| 久久久久国产网址| 六月丁香七月| 国产午夜福利久久久久久| 熟女人妻精品中文字幕| 亚洲真实伦在线观看| 欧美极品一区二区三区四区| 精品久久久久久电影网 | 我的女老师完整版在线观看| 亚洲av成人精品一区久久| 少妇的逼好多水| 亚洲成av人片在线播放无| 岛国在线免费视频观看| 欧美日韩综合久久久久久| 1024手机看黄色片| 亚洲精品日韩在线中文字幕| 成人二区视频| www.色视频.com| 国产欧美日韩精品一区二区| 美女内射精品一级片tv| 久久99精品国语久久久| 国产精品麻豆人妻色哟哟久久 | 精品99又大又爽又粗少妇毛片| 国产精品爽爽va在线观看网站| 日本黄色视频三级网站网址| 成人亚洲精品av一区二区| 国产视频首页在线观看| 成年女人看的毛片在线观看| 亚洲av电影不卡..在线观看| 亚洲最大成人av| 午夜福利在线观看免费完整高清在| 国产精品一二三区在线看| 午夜a级毛片| 成人一区二区视频在线观看| 少妇裸体淫交视频免费看高清| h日本视频在线播放| 大香蕉97超碰在线| 亚洲精品,欧美精品| 18禁动态无遮挡网站| 国产成年人精品一区二区| 国产成人午夜福利电影在线观看| 久久精品久久精品一区二区三区| 你懂的网址亚洲精品在线观看 | 亚洲精品久久久久久婷婷小说 |